 The majority of analysts on Wall Street recommend buying Better Therapeutics Inc. BTTX , Financial and Ginkgo Bioworks Holdings Inc. DNA , Financial shares. That is surprising given these two stocks havent performed well over the past 52 weeks ending May 10. 